BWX Technologies Inc.
BWX Technologies, Inc. (BWXT)
Overview
BWX Technologies, Inc. is an American specialty manufacturer of nuclear components and a nuclear technology/services provider headquartered in Lynchburg, Virginia, with an operating history of more than 100 years dating back to its predecessor The Babcock & Wilcox Company. It is a mid-to-large-cap industrial/defense company that designs, engineers, and manufactures precision naval nuclear reactors, reactor components, and nuclear fuel for the U.S. government, alongside a growing commercial nuclear power and medical radioisotope business. For fiscal year 2025, BWXT reported total revenue of $3.198 billion (up 18% year-over-year), a record backlog of $7.3 billion (up 50% year-over-year) driven by large multi-year naval propulsion and commercial nuclear awards, and 2026 guidance of roughly $3.75 billion in revenue, reflecting continued strong demand for both defense nuclear work and civilian nuclear power expansion.
What They Do & How They Make Money
BWXT makes money primarily by manufacturing highly engineered, safety-critical nuclear components under long-term U.S. government contracts, supplemented by a smaller but fast-growing commercial nuclear equipment and medical isotope business. Its core government business involves designing and manufacturing naval nuclear reactors and components for U.S. Navy submarines and aircraft carriers under the Naval Nuclear Propulsion Program, as well as operating and managing government-owned nuclear facilities and developing advanced reactor technologies for NASA, the Department of Defense, and the Department of Energy. This work requires extraordinary technical certification, security clearances, and decades of qualification history, making BWXT (together with a very small handful of other qualified suppliers) one of only a few companies in the world capable of performing it — a position that generates highly durable, multi-year, cost-plus and fixed-price government revenue. Commercially, BWXT manufactures nuclear steam generators, heat exchangers, pressure vessels, and reactor components for utilities and equipment makers, and separately produces medical radioisotopes, radiopharmaceuticals, and medical devices used in cancer diagnosis and treatment — a segment that nearly doubled in 2025 on rising demand for nuclear medicine and new commercial nuclear power investment (including small modular reactor supply chains).
Business Segments
BWXT reports two reportable segments:
- Government Operations — Manufactures naval nuclear reactors and components for the U.S. Navy, manages and operates government-owned nuclear facilities, and develops advanced reactor technologies for NASA, DoD, and DOE. FY2025 revenue of about $2,350.1 million (up 8% year-over-year), the larger and more stable of the two segments, underpinning the bulk of the record backlog.
- Commercial Operations — Designs and manufactures commercial nuclear steam generators, heat exchangers, pressure vessels, and reactor components, and produces medical radioisotopes, radiopharmaceuticals, and medical devices. FY2025 revenue of about $853.1 million, up a striking 63% year-over-year, reflecting both commercial nuclear power expansion (including a Cambridge, Ontario manufacturing facility expansion) and growing medical isotope sales.
Competitors
BWXT's two segments face very different competitive dynamics:
- Government Operations: Competition is limited given extreme technical, security, and regulatory barriers; competitors referenced in its 10-K for adjacent government nuclear services and facility management work include Bechtel National, Amentum, Fluor Corporation, and Northrop Grumman, though BWXT holds a uniquely entrenched position as a qualified naval reactor component manufacturer.
- Commercial Operations: Competes with Framatome, Cameco Corporation, and Westinghouse Electric Corporation on price, technical capability, quality, and delivery timeliness for commercial nuclear equipment, and with various radiopharmaceutical and medical isotope producers in its medical business.
Competitive Position
BWXT's core advantage is its position as one of a tiny handful of companies in the world qualified, certified, and security-cleared to manufacture naval nuclear reactor components for the U.S. Navy — a technical and regulatory moat built over decades that would be exceptionally difficult and slow for any new entrant to replicate, and which drives highly visible, multi-year backlog growth (up 50% in 2025 alone). This defense franchise is complemented by a commercial nuclear and medical isotope business that is scaling quickly amid renewed global interest in nuclear power (including small modular reactors) and rising demand for nuclear medicine, giving BWXT a second, faster-growing growth vector beyond its steady government base. Key risks include concentration in U.S. government/defense spending and program timing (budget or program delays could affect a large share of revenue), execution risk in scaling commercial manufacturing capacity fast enough to capture nuclear power's resurgence, competition from larger and more diversified nuclear equipment makers like Westinghouse and Framatome in commercial markets, and the inherent complexity/cost overrun risk in large, first-of-a-kind nuclear manufacturing programs. BWXT's combination of a near-monopoly defense franchise and a rapidly expanding commercial/medical growth engine gives it an unusually durable and improving competitive position relative to most industrial peers.